초록 ▼

The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therape

The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.

대표청구항 ▼

1. A synthetic RNA molecule comprising: a) a first 15-25 residue oligonucleotide having a sequence that is 80-100% identical to a mature miR-7 sequence;b) a second 15-25 residue oligonucleoLide having a sequence that is 60-100% identical to a sequence complementary to the mature miR-7 sequence; andc

1. A synthetic RNA molecule comprising: a) a first 15-25 residue oligonucleotide having a sequence that is 80-100% identical to a mature miR-7 sequence;b) a second 15-25 residue oligonucleoLide having a sequence that is 60-100% identical to a sequence complementary to the mature miR-7 sequence; andc) at least one ofi) a replacement group for the phosphate or the hydroxyl of the nucleotide at the 5′ end of the second oligonucleotide, andii) one or more sugar modifications in the first or last 1-6 residues of the second oligonucleotide. 2. The synthetic RNA molecule of claim 1, comprising a replacement group for the phosphate or the hydroxyl of the nucleotide at the 5′ end of the second oligonucleotide. 3. The synthetic RNA molecule of claim 2, wherein the replacement group is biotin, an amine group, a lower alkylamine group, an acetyl group, 2′O-Me, DMTO, fluoroscein, a thiol, or acridine. 4. The synthetic RNA molecule of claim 2, wherein the phosphate of the nucleotide at the 5′ end of the second oligonucleotide is replaced. 5. The synthetic RNA molecule of claim 4, wherein the replacement group is a lower alkylamine group. 6. The synthetic RNA molecule of claim 2, wherein the hydroxyl of the nucleotide at the 5′ end of the second oligonucleotide is replaced. 7. The synthetic RNA molecule of claim 1, comprising one or more sugar modifications in the first or last 1-6 residues of the second oligonucleotide. 8. The synthetic RNA molecule of claim 7, wherein the sugar modification is a 2′O-Me modification. 9. The synthetic RNA molecule of claim 7, comprising one or more sugar modifications in the first 1-6 residues of the second oligonucleotide. 10. The synthetic RNA molecule of claim 7, comprising one or more sugar modifications in the last 1-6 residues of the second oligonucleotide. 11. The synthetic RNA molecule of claim 7, comprising one or more sugar modifications in the first or last 2 to 4 residues of the second oligonucleotide. 12. The synthetic RNA molecule of claim 1, further comprising a noncomplementarity between one or more nucleotide in the last 1-5 residues at the 3′ end of the second oligonucleotide and the corresponding nucleotides of the First oligonucleotide. 13. The synthetic RNA molecules of claim 1, further comprising a noncomplementarity between two or more nucleotides in the last 1-5 residues at the 3′ end of the second oligonucleotide and the corresponding nucleotides of the first oligonucleotide. 14. The synthetic RNA molecule of claim 1, comprising i) and ii). 15. The synthetic RNA molecule of claim 12, comprising i) and ii). 16. The synthetic RNA molecule of claim 1, wherein time first oligonucleotide is 90-100% identical to the mature miR-7 sequence. 17. The synthetic RNA molecule of claim 1, wherein the first oligonucleotide is 100% identical to the mature miR-7 sequence. 18. A pharmaceutical composition comprising the synthetic RNA of claim 1 and a liposomal delivery vehicle. 19. A method of reducing lung cancer cell viability or inducing apoptosis in a lung cancer cell comprising introducing into the lung cancer cell an effective amount of a synthetic RNA molecule comprising: a) a first 15-25 residue oligonucleotide having a sequence that is 80-100% identical to a mature miR-7 sequence; andb) a second 15-25 residue oligonucleotide having a sequence that is 60-100% identical to a sequence complementary to the mature miR-7 sequence; andc) at least one ofi) a replacement group for the phosphate or the hydroxyl of the nucleotide at the 5′ end of the second oligonucleotide, andii) one or more sugar modifications in the first or last 1-6 residues of the second oligonucleotide. 20. The method of claim 19, wherein: i) the phosphate or the nucleotide at the 5′ end of the second oligonucleotide is replaced with a lower alkylamine group, orii) one or more sugar in the first or last 1-6 residues of the second oligonucleotide has a 2′O-Me modification. 21. The method of claim 19, wherein the cancer cell is a human cell. 22. The method of claim 19, wherein the cancer cell is in a human. 23. A method of treating lung cancer comprising introducing into a lung cancer cell an effective amount of a synthetic RNA molecule comprising: a) a first 15-25 residue oligonucleotide having a sequence that is 80-100% identical to a mature miR-7 sequence; anda second 15-25 residue oligonucleotide having a sequence that is 60-100% identical to a sequence complementary to the mature miR-7 sequence; andc) at least one ofi) a replacement group for the phosphate or the hydroxyl of the nucleotide at the 5′ end of the second oligonucleotide, andii) one or more sugar modifications in the first or last 1-6 residues of the second oligonucleotide. 24. The method of claim 23, wherein: i) the phosphate of the nucleotide at the 5′ end of the second oligonucleotide is replaced with a lower alkylamine group, orii) one or more sugar in the first or last 1-6 residues of the second oligonucleotide has a 2′O-Me modification. 25. The method of claim 23, wherein the cancer cell is a human cell. 26. The method of claim 23, wherein the cancer cell is in a human. 27. The method or claim 19, wherein the first oligonucleotide is 100% identical to the mature miR-7 sequence. 28. The method or claim 23, wherein the first oligonucleotide is 100% identical to the mature miR-7 sequence.